Skip to main content
Premium Trial:

Request an Annual Quote

Miraculins Signs on Investment Firm Bloom Burton for Financial Advice

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Miraculins today said that it has signed on investment firm Bloom Burton as an advisor to the company.

Bloom Burton, based in Toronto, will provide strategic and financial services, including an overview and analysis of potential opportunities, financial modeling, analysis of Miraculins' business plan, an overview and assessment of financing options, and strategic partnership opportunities, Miraculins said.

Christopher Moreau, president and CEO of Winnipeg, Manitoba-based Miraculins, said in a statement that Bloom Burton's "in-depth knowledge of the healthcare industry and their expertise in finance and investment banking brings clear value to our business and our shareholders as we advance our technology platforms."

The Scan

Transplant Tests Edited Pig Kidneys

The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient.

UK Changes Some Gene-Edited Crop Rules

A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says.

Pill Works Against Omicron in Lab

Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports.

Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas

In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.